Review

STAT3 signaling in ovarian cancer: a potential therapeutic target

Renba Liang, Xishan Chen, Li Chen, Fangzhu Wan, Kaihua Chen, Yongchu Sun, Xiaodong Zhu

Department of Radiation Oncology, Guangxi Medical University Cancer Hospital and Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, P.R. China

Corresponding author: Xiaodong Zhu, Address: Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71 He Di Road, Nanning 530021, Guangxi, China. Tel.: +86-13978873616; E-mail: zhuxdonggxmu@126.com

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.03.18; Accepted: 2019.09.08; Published: 2020.01.01

Abstract

Accumulating evidence has shown that Signal Transducer and Activator of Transcription 3 (STAT3) is thought to be a promising target for cancer therapy as STAT3 is frequently overexpressed in a wide range of cancer cells as well as clinical specimens, promoting tumor progression. It is widely accepted that STAT3 regulates a variety of cellular processes, such as tumor cell growth, survival, invasion, cancer stem cell-like characteristic, angiogenesis and drug-resistance. In this review, we focus on the role of STAT3 in tumorigenesis in ovarian cancer and discuss the existing inhibitors of STAT3 signaling that can be promisingly developed as the strategies for ovarian cancer therapy.

Key words: STAT3, ovarian cancer, tumorigenesis, inhibitors

Introduction

Signal Transducer and Activator of Transcription 3 (STAT3) is a member of STAT family proteins which includes STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. Studies have identified that STAT3 consists of several distinct domains: the N-terminal domain crucial for dimer-dimer interaction, the coiled-coil containing protein interaction domain, the DNA binding domain (DBD), the linker domain, the Src-homology 2 (SH2) domain binding to related receptors, the domain containing tyrosine residue at position 705 (Tyr-705), and the C-terminal domain necessary for transcriptional activation. In general, STAT3 emerges as an inactive state located in the cytoplasm. STAT3 is activated through phosphorylation of Tyr-705 by binding to the cytoplasmic part of receptor tyrosine kinases including EGFR, or by receptor associated kinases including JAK (Janus kinase), or non-receptor kinases including Src, or diverse stimulation. Activated STAT3 forms homodimers or heterodimers through reciprocal pTyr-SH2 interaction, then translocate into nucleus and bind to special elements of STAT3-targeted genes, subsequently resulting in the transcription of these genes, such as Bcl2, c-myc, cyclinD1, survivin, MMP2 and MMP9. Ultimately, these genes exhibit their biofunction promoting tumorigenesis and progression.

Figure 1. Linear topology of STAT3 structure. As shown, STAT3 is made up of the N-terminal domain, the coiled-coil domain, the DNA binding domain (DBD), the linker domain, the Src-homology 2 (SH2) domain, and the C-terminal domain. The tyrosine residue at position 705 (Tyr-705) is close to SH2 domain.
Ovarian cancer is one of the most lethal gynecological malignancies among women. According to the origin of tissue, ovarian tumor can be classified into distinct types, including epithelium cell tumor, stromal endocrine cell tumor, and germ cell tumor. Moreover, epithelial ovarian cancer (EOC), as a heterogeneous disease and accounting for over 90% of primary ovarian tumors, can also be divided into several different subtypes, such as serous, clear cell, mucinous, endometrioid, transitional cell, mixed, and undifferentiated type. Unfortunately, ovarian cancer has frequently reached advanced stage when patients are at the time of diagnosis. Therefore, it is of great importance to identify the signaling pathway involved in tumorigenesis and progression of ovarian cancer.

Interestingly, a significant body of evidence has highlighted the importance of STAT3 signaling, which is aberrantly activated in ovarian cancer cell lines and tissue samples detecting by microarray analysis, real-time reverse transcription-PCR, western blot as well as luciferase reporter, and associated with ovarian tumor development. The STAT3 signaling is critical for ovarian cancer progression, such as promoting cell proliferation, survival, invasion, stem cell-like characteristic, angiogenesis and chemoresistance. Conversely, inhibition of STAT3 activation results in the dramatic suppression of tumor growth, suggesting that STAT3 signaling is a promising target for ovarian cancer therapy. Thus, it is crucial to have a full understanding of functions of STAT3 in ovarian cancer in order to develop effective therapeutic interventions for ovarian cancer.

In this review, we focus on the role of STAT3 in tumorigenesis of ovarian cancer and summarize the existing agents targeting STAT3 signaling that can be potentially developed as the strategies for ovarian cancer treatment.

Role of STAT3 in tumorigenesis in ovarian cancer

Studies demonstrates that STAT3 signaling be involved in cell proliferation, survival, invasion, stem cell-like characteristic, angiogenesis and chemoresistance. Invasion and invasiveness

Invasion and metastasis are one of the most important characteristics of malignant tumors. Increasing number of evidence has demonstrated that STAT3 is frequently activated in ovarian carcinoma specimens, especially in high-grade type, and plays a crucial role in the migration and invasiveness of human ovarian cancer. The STAT3 signaling is critical for ovarian cancer progression, such as promoting cell proliferation, survival, invasion, stem cell-like characteristic, angiogenesis and chemoresistance. Conversely, inhibition of STAT3 activation results in the dramatic suppression of tumor growth, suggesting that STAT3 signaling is a promising target for ovarian cancer therapy.

In ovarian cancer, STAT3 is activated via phosphorylation of Tyr-705 by growth factor receptor tyrosine kinases, cytokine receptor associated kinases (JAK), and non-receptor kinases (Src). After activation, STAT3 forms dimerization and translocate into nucleus, in which they bind to promoter of STAT3-targeted genes, resulting in gene transcription.
Figure 3. STAT3-targeted genes and their role in tumorigenesis/progress. Persistent activation of STAT3 promotes its-regulated genes expression, which contribute to ovarian cancer growth, survival, invasion, angiogenesis, stem cell-like characteristic, and chemo-resistance.

Epithelial-mesenchymal transition (EMT), which is marked by the downregulation of epithelial markers, such as E-cadherin, together with over-expression of mesenchymal markers, such as N-cadherin, Vimentin and snail, frequently occurs during the process of invasion and migration in tumor. It is reported that constitutively activated STAT3 is involved in EMT of ovarian cancer, as evidenced by the upregulation of Vimentin in STAT3-active cells. In addition, investigations in the last decade have identified that epidermal growth factor (EGF) and its receptor (EGFR) as well as IL-6, which frequently upregulated in ovarian cancer, are crucial mediators of EMT. Activated EGFR increases the level of N-cadherin and Vimentin, in line with activation of STAT3 and IL-6 production. Stimulating ovarian cancer cells with IL-6 promotes STAT3 phosphorylation and cell migration. Moreover, selectively blocking STAT3 signaling brings about the loss of Vimentin, N-cadherin, IL-6 as well as cell movement.

Growth and survival

The crucial role of STAT3 in facilitating tumor cell growth and survival has been well-established. At the molecular level, events at quite an early stage have indicated that constitutive activation of STAT3 has a strongly correlation with high levels of Bcl-xL, cyclin D1 and c-myc. STAT3 knockdown with specific small interfering RNA causes a loss of cell growth and induces apoptosis in human ovarian cancer cells, consistent with down-regulation of cyclin D1 and survivin level. In addition, support for these finding further is provided by the evidence that treating human ovarian cancer with STAT3 inhibitor HO-3867, a novel compound which decreases the level of Tyrosine-phosphorylated STAT3 (pSTAT3) and then followed by a decline of cyclin D1, survivin and Bcl-2 as well as an ascent of cleaved PARP, caspase-3 and caspase-7, gives rise to suppression of cell proliferation and survival. Similarly, SD-1029 or SD-1008, a small molecule against JAK, induces apoptosis of ovarian cancer cells by cut-down of Bcl-X(L) and survivin expression through inhibition of STAT3 phosphorylation.

Angiogenesis

It has been proved that angiogenesis, a process pivotal for nutrition supply for tumor growth and metastasis, is a common phenomenon in malignant disease. Vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α) are two key molecules in promoting angiogenesis. It is interesting to note that STAT3 regulates VEGF expression, directly binding to the VEGF promoter and strengthening expression of VEGF and tumor angiogenesis. Blocking STAT3 signaling with STAT3 decoy inhibits VEGF expression and decreases...
tumor volumes. Furthermore, comparing with non-carcinoma tissues, primary ovarian epithelial carcinoma samples have higher level of pSTAT3 and VEGF. Likewise, a study has found that IL6-STAT3-HIF signaling is abnormally upregulated in ovarian clear cell cancer samples and patients with such disease achieve clinical responses when administrated with sunitinib, a angiogenesis inhibitor. Beside primary ovarian cancer sample, STAT3 is also activated in ascites-derived ovarian cancer cells (ADOCCs). HO-3867 deeply inhibits vessel formation and tumor growth in orthotopic mouse model through antagonizing STAT3. In addition, it is commonly accepted that cancer stem cells (CSCs) possess property of tumorigenesis including involving in angiogenesis. Similar to this knowledge, a recent study suggests ovarian cancer stem-like cells (CSLCs) are capable of differentiating into endothelial cells (ECs) and forming microtube network in the presence of chemokine CCL5. Notably, CCL5 signaling activates the NF-kB and STAT3 signal pathways, then facilitating tumor angiogenesis. HIF-1α is another key modulator of angiogenesis. Importantly, STAT3 plays a vital role in regulating HIF-1α expression. The same results are also found in ovarian cancer cells. Treating six ovarian cancer cell lines with diindolylmethane decreases activity of cell invasion and angiogenesis through downregulating expression of HIF-1α and VEGF via targeting STAT3.

Cancer stem cell-like characteristic

Cancer stem cells (CSCs), similar to normal stem cells (SCs), have the potential of self-renewal and differentiation. Studies more than a decade ago have suggested that CSCs exist in ovarian cancer and are believed to participate in chemoresistance, recurrence and angiogenesis. Interestingly, activation of STAT3 is involved in a CSC-like residual population of ovarian cancer cell after treatment with paclitaxel. Inhibiting JAK2/STAT3 pathway brings about restraint of CSC-like characteristics in paclitaxel-treated residual cells in vitro and a rapid decline of tumor burden in vivo as expected. Spheroids, known as aggregates of some malignant cells, are abundant in ovarian CSCs identified by high level of ALDH1A1 and β-catenin, which are widely considered as CSC markers. Moreover, recent studies have demonstrated that STAT3 correlates with spheroid formation, and c-myc, previously reported to be modulated by STAT3, is found increasing in ovarian cancer spheroids. In addition, CD24 (another CSC marker) positive ovarian cancer cells promote spheroid formation and improve tumor-initiating capacity, accompanied by increased level of pSTAT3 and STAT3 target genes, also known as stem cell genes Nanog and c-myc, further suggesting that STAT3 has a tight relationship with CSCs or CSC-like phenotypes.

Induction of chemotherapy resistance

Ovarian cancer is one of leading causes of death of patients with gynecologic cancer. Systematic chemotherapy after the cytoreductive surgery is identified standard treatment of advanced ovarian cancer. Although initial response to chemotherapy agents, especially platinum and taxane, is high, most cases unfortunately become chemoresistance, resulting in disease recurrence ultimately. Therefore, a great number of studies are designed to understand the underlying mechanisms by which ovarian cancer develops resistance to chemotherapeutic agents.

Emerging evidence has suggested that pSTAT3 is highly expressed in paclitaxel- and cisplatin-resistant ovarian cancer cells. Inhibition of STAT3 activity reverses chemoresistance and enhances chemotherapeutic drugs-induced apoptosis, accompanied by decreased level of pro-survival genes Bcl-xL, Bcl-2 and survivin. These results are in parallel with the findings that it increases toxicity of cisplatin or paclitaxel to ovarian cancer when treated with JAK2 or STAT3 inhibitor, such as AG490, WP1066, Diindolylmethane, SD-1029, and SD-1008. Moreover, a recent study reveals that STAT3 polymorphisms may function as an independent marker predicting a poor response to chemotherapy for patients with advanced serous EOC.

Recently, investigations demonstrate that tumor microenvironment, being make up of tumor cells, mesenchymal cells and different kinds of cytokines, is involved in chemoresistance in cancer cells. Carcinoma-associated fibroblasts (CAFs), known to increase chemoresistance in tumor cells, are the key components of mesenchymal cells in tumor microenvironment. Importantly, CAFs protect ovarian cancer cells from cisplatin cytotoxicity through activating STAT3 signaling. In addition, CAFs secret abundant IL-6. Strengthening EMT via IL-6/JAK2/STAT3 pathway results in paclitaxel resistance in ovarian cancer.

Inhibitor of STAT3 signaling in ovarian cancer

As discussed above, abnormal activated STAT3 plays a crucial role in tumor properties such as migration, invasiveness, proliferation, survival, angiogenesis, cancer stem cell-like characteristic, and chemoresistance in ovarian cancer, driving it to act as a promising therapeutic target to manage this kind.
disease. To date, a lot of approaches have been carried out around inhibiting STAT3 signaling, such as using small molecules from natural sources, synthetic agents and anti-sense oligonucleotide. Here, we will provide an outlook into natural (Figure 4) and synthetic (Table 1) inhibitors of STAT3 signaling that have been shown to be effective in ovarian cancer management.

Table 1. Synthetic inhibitors targeting STAT3 directly or indirectly in ovarian cancer.

| Agent       | Target                  | References |
|-------------|-------------------------|------------|
| HO-3867     | DNA-binding domain      | 42-44, 38, 135-137 |
| HO-4200     | DNA-binding domain      | 138        |
| H-4318      | DNA-binding domain      | 138        |
| LC28        | DNA-binding domain      | 140        |
| STAT3 ODN   | DNA-binding domain      | 143        |
| Static      | SH2 domain              | 73         |
| AG490       | JAK2                    | 150        |
| Momelotinib (CYT387) | JAK2            | 151        |
| Ruxolitinib | JAK2                    | 71         |
| AZD1480     | JAK2                    | 153        |
| WP1066      | JAK2                    | 154        |
| SD-1029     | JAK2                    | 45         |
| ML5-2384    | JAK2/ Src               | 155        |
| Erlotinib   | EGFR                    | 160        |
| Cetuximab   | EGFR                    | 161        |
| Gefitinib   | EGFR                    | 162        |
| Lapatinib   | EGFR                    | 163        |
| Dasatinib   | Src                     | 167, 168   |
| Saratinib   | Src                     | 169        |
| Siltuximab  | IL-6                    | 174, 175   |
| Tocilizumab | IL-6R                   | 176, 177   |
| siRNA-PLGA/CSO | STAT3               | 179        |
| Oncolytic adenovirus (M4) | STAT3            | 181        |

Natural STAT3 inhibitors in ovarian cancer

Standard chemotherapy is indispensable part of ovarian cancer treatment. Despite high sensitivity to chemotherapy, most of patients ultimately become chemoresistance. Moreover, chemotherapy drugs not only have potential to kill cancerous cells, but also generate severe toxic side effects on normal tissues and cells. These side effects limit clinical high dose use, prolong total treatment time, or even results in treatment interruption, which has a negative impact on patient's prognosis. Hence, researchers are working hard to find low-toxic and highly effective anti-tumor drugs, and natural products are an obvious example. Natural compounds are the basis of drug discovery and design, and most of anticancer drugs originate from natural products89. Under the efforts of researchers, to date, several natural compounds against STAT3 signaling are explored in preclinical trial or clinical trial in ovarian cancer.

Resveratrol

Resveratrol, a natural compound with antioxidant and anti-inflammatory function, is derived from red grapes and berries and has drew people's great attention. Resveratrol is thought to be preventive agent of cardiovascular disease90. There is also growing evidence that resveratrol possesses anti-tumor potential in a great number of cancers, including ovarian cancer91-96. Zhong et al found that resveratrol inhibits cell proliferation and enhances apoptosis of ovarian cancer, and activated STAT3 is the molecule target of resveratrol37. Similar to this finding, a recent study suggests that resveratrol suppresses growth, increases apoptosis as well as autophagic activity in ovarian cancer cells, presumably through blocking STAT3 signaling pathway97. In addition, IL-6, a pro-inflammatory cytokine which are able to activate STAT326, promotes cell invasion and metastasis, accompanied by autophagy formation and down-regulation of ARHI (A Ras homologue member I), an imprinted tumor-suppressor gene known to suppress cell growth and motility. On the contrary, resveratrol neutralizes the effect of IL-6 on ovarian cancer cells and reduces level of STAT3 expression95. Furthermore, a latest report has demonstrated that ARHI is upregulated, in paralleled with decreased of STAT3 in ovarian cancer cells treated with resveratrol98. Altogether, preclinical practices show that resveratrol elicits antitumor effect on ovarian cancer cells. However, there is no clinical trial to assess resveratrol's property in patients with ovarian cancer. Additionally, despite phase I study conducted in patients with colorectal cancer and in healthy volunteers finds resveratrol consumed 5.0 g daily 14 days is safe and well tolerated99-101, it still warrants further clinical investigations to evaluate its clinical activity.

[Figure 4. Chemical structures of natural inhibitors of STAT3 in ovarian cancer.]
Curcumin

Curcumin (diferuloylmethane) is a phenolic component extracted from turmeric (Curcuma longa) and is often used as a food additive spice. Intriguingly, modern studies have found that curcumin has more functions than just dietary spice, such as anti-inflammatory and anti-cancer effects. Curcumin is involved in the inhibition of transformation, survival, and metastasis in cancer. For example, treating ovarian cancer cells with curcumin suppresses activation of STAT3, resulting in decreased cell viability. Moreover, targeting STAT3 phosphorylation by which curcumin inhibits invasion and metastasis of ovarian cancer cells. Apart from the STAT3 pathway, curcumin also inhibits characteristics of ovarian cancer via blocking the other signaling, including sarco/endoplasmic reticulum calcium ATPase, PI3K/Akt and nuclear factor-kappaB pathway. Aside from its functions, it is a surprising finding that curcumin is very safe even at a high dose of oral 12 g per day in humans. Unfortunately, one main drawback to limit its use in medical application is rapid metabolism and low bioavailability. As a consequence, many approaches have been adopted to circumvent this problem, including engineering its analogs by modulating curcumin structure and improving its delivery systems through loading in nanoparticles. Take HO-3867 for example. HO-3867, a curcumin analog, exhibits substantially higher anticancer efficacy than the parent curcumin. In all, improving its bioavailability, curcumin may be a great potential candidate as an anti-tumor drug in ovarian cancer.

Corosolic acid

Corosolic acid, a natural triterpenoid compound derived from banaba leaves and apples, has been shown to have anti-tumor effects on a variety of tumor models, such as glioblastoma, prostate cancer, retinoblastoma, renal carcinoma, gastric cancer, breast cancer, liver cancer, colon cancer, lung adenocarcinoma, cervix adenocarcinoma, and osteosarcoma. Similar to curcumin and resveratrol, CA is a potent STAT3 inhibitor, suppressing cell growth of ovarian cancer and glioblastoma by abrogating STAT3 activity. Moreover, since aberrantly activated STAT3 is strongly associated with chemoresistance as mentioned above, CA also enhances cytotoxicity of chemotherapeutic drugs to ovarian cancer cells via inhibition of STAT3 activation. Additionally, tumor microenvironment, as discussed previously, participates in progress of tumor and tumor-associated macrophages (TAMs) of M2 phenotype is a component of tumor microenvironment. Recent research indicates M2 macrophages regulate cell growth and metastasis of ovarian cancer, and STAT3 is activated in ovarian cancer cells when coculturing with M2 macrophages. Interestingly, CA reduces STAT3 activity in ovarian cancer cells through inhibiting M2 polarization of macrophages. Although the studies of CA in ovarian cancer is relatively rare comparing to curcumin and resveratrol, effects of CA have been well established in certain cancer models, providing rational evidence for conducting further investigations on it and developing it as an inhibitor in ovarian cancer.

Synthetic blockers of STAT3 signaling in ovarian cancer

As discussed above, because of rapid metabolism or delivery systems, some natural compounds have low bioavailability in serum. Hence, it is necessary to design corresponding analogues or synthesize other novel small molecules that can inhibit STAT3 activation. Besides, given that STAT3 is made up of distinct domains and activated by receptor tyrosine kinases, or receptor-associated kinases, or non-receptor kinases, or diverse cytokines, synthetic agents targeting STAT3 signaling are mainly classified into the following categories in ovarian cancer: 1) direct inhibitors targeting the domains of STAT3; 2) indirect inhibitors targeting the upstream factors.

Direct inhibitors of STAT3

By targeting the DNA-binding domain, N-terminal domain, SH2 domain of STAT3, direct inhibitors interfere with STAT3 activation, resulting in the blockage amplification of STAT3 signaling cascade reaction and concomitantly the decrease of STAT3-regulated gene level.

Therefore, specific domains of STAT3, in theory, are promising targets for designing STAT3 inhibitors. So far, there are some direct inhibitors which interact with the DNA-binding domain in preclinical trial of ovarian cancer. For example, HO-3867, one of diaryldenylpiperidone(DAP)-based synthetic compounds, also known as curcumin analog, directly binds to the STAT3 DNA-binding domain and exclusively inhibits activation of STAT3 without interfering with that of other member of STATs. HO-3867 decreases migration of human ovarian cancer cells. Furthermore, compared with non-transformed cells and tissues, HO-3867 exerts more toxicity, including increasing apoptosis and inhibiting tumor growth, on both in vitro and in vivo using xenograft model. These findings are strongly supported by the results of several reports. Similar to HO-3867, HO-4200 and H-4318 are two derivatives of DAP
compounds that selectively interact with DNA-binding domain of STAT3. Treating cisplatin-resistant ovarian cancer cells with HO-4200 and H-4318 decreases the level of STAT3 target proteins: c-myc, Bcl-2, Bcl-xL, survivin and cyclin D1/D2, giving rise to inhibition of cell survival and induction of apoptosis. In addition, HO-4200 and H-4318 also inhibit VEGF expression and decrease migration/invasion activity.

Besides DAP compounds, LC28, designed on the basis of pharmacophore of a STAT3 inhibitor inS3-54139, is another new inhibitor targeting the DNA-binding domain of STAT3140. Huang and co-workers have identified that LC28 significantly inhibits growth of cisplatin-resistant ovarian cancer cells by blocking interaction between STAT3 and DNA140. Beside the inhibitors mentioned above, STAT3 decoy oligodeoxynucleotides (ODN) is another strategy inhibiting DNA binding activity of STAT3141. The STAT3 decoy is a double-stranded oligonucleotide binding to STAT3 with a high specificity, and it exhibits anti-proliferation capacity on head and neck cancers as a phase 0 clinical trial shows142. Furthermore, in addition to head and neck cancers, an investigation conducted by Zhang et al has revealed that STAT3 decoy ODNs also induces cell apoptosis in xenograft mode of ovarian cancer143.

The SH2 domain of STAT3 is extremely important not only for recognition of related receptors, but also for dimerization of STAT3 itself or with other members of STAT family. Then STAT3 is phosphorylated and activated, subsequently translocate into nucleus to realize its biological function. Hence, the SH2 domain provides us an attractive opportunity for designing specific STAT3 inhibitors. Compared with inhibitors targeting DBD, the number of agents that inactivate SH2 domain is quite few in ovarian cancer. However, investigators still do all they can do to design new inhibitors directly acting on the SH2 domain. Stattic is an obvious example. Schust et al have suggested that Stattic, a nonpeptidic small molecule, directly inhibits the SH2 domain of STAT3, leading to inactivation of STAT3 and apoptosis of STAT3-dependent cancer cells144. More interestingly, as abnormally activated STAT3 plays a critical role in chemoresistance mentioned above, stattic improves the sensitivity of chemoresistant ovarian cancer cell to cisplatin both in vitro and in vivo73.

Apart from DBD and SH2 domain, the N-terminal domain is a vital component of STAT3. The N-terminal domain, also called oligomerization domain, has eight helices mediating tetramerization of two STATs dimers and interaction with other proteins145. The forming complex may influence transcriptional activity of STAT3, indicating that the N-terminal domain of STAT3 regulates transcription of STAT3 targeted genes which are involved in tumor progress146. Therefore, agents targeting the N-terminal domain may potentially show anticancer efficacy. ST3-H2A2, a highly selective inhibitor of the N-terminal domain of STAT3, suppresses STAT3 signaling147. ST3-H2A2 induces expression of proapoptotic genes in cancer cells (PC3, DU145 prostate cancer cells and MCF-7, MDA-MB-231 breast cancer cells), but not in normal epithelial cells (prostate epithelial cells RWPE-1 and human mammary epithelial cells (HMEC)), resulting in apoptotic death of cancer cells147. Unfortunately, to date, there is no inhibitors of the N-terminal domain reported in the ovarian cancer.

**Indirect inhibitors of STAT3**

STAT3 signaling pathway is a cascade amplification reaction activated by either upstream kinases or diverse cytokines, such as JAK, EGFR, Src as well as IL-6. As a result, these upstream factors are attractive strategies to disturb the activation of STAT3 and there are existing several inhibitors targeting them after long years ongoing efforts. AG490 is an inhibitor of JAK2148. Studies have suggested that AG490 exerts anti-tumor effects on several cancers, including acute lymphoblastic leukaemia148, head and neck squamous cell carcinoma149, ovarian cancer150 and so on. Moreover, AG490 reverses paclitaxel resistance through decreasing the level of pSTAT3 and multidrug resistance protein 1 in ovarian cancer cells150. However, there is no clinical trial of AG490 in malignancies in spite of its anti-tumor efficacy in the preclinical studies. Momelotinib and ruxolitinib both are JAK inhibitors and they have been well proved to suppress ovarian cancer growth71, 151. Despite the fact that ruxolitinib is used in clinical practice in myelofibrosis and momelotinib treatment was noninferior to ruxolitinib for spleen response in Janus kinase inhibitor-naïve patients with myelofibrosis reported by a phase III randomized trial152, there is no clinical trial conducted in ovarian cancer. Hence, this may be next step of our work. Except for AG490, Momelotinib and ruxolitinib, there are other existing JAK inhibitors, such as AZD1480153, WP1066154, SD-102945, and MLS-2384155 also having anti-tumor property in ovarian cancer model. It is of particular note here that although AZD1480 confers anti-tumor effects on ovarian cancer in preclinical research, few further studies have been performed in clinical. The possible reason for this phenomenon may be the severe side effect on nervous system when treating myelofibrosis with AZD1480 as a phase I clinical trial reported156.
Beside JAK inhibitors, the EGFR inhibitor is another way to inactivate STAT3 indirectly. Preclinical evidence reveals that EGFR inhibitors, such as Erlotinib, Cetuximab, Gefitinib and lapatinib, decrease the expression of STAT3. Nevertheless, such inhibitors have minimal clinical activity or do not improve progression-free or overall survival in the treatment of patients with ovarian cancer. One possible reason for this phenomenon may be the feedback activation of STAT3 signaling pathway in the long run.

Src is a cell membrane-associated non-receptor tyrosine kinase and plays a critical role in proliferation, migration, and differentiation of tumor cells. At the molecular level, activation of Src results in initiating of STAT3 pathway. Therefore, Src is also served as an attractive therapeutic target for cancer management. In fact, a Phase II trial conducted by The Gynecologic Oncology Group has demonstrated that dasatinib, an oral Src inhibitor, shows limited efficacy in patients with recurrent epithelial ovarian cancer when administered alone. However, A recent study suggests that the combination of dasatinib with paclitaxel generates synergistic inhibition in growth of ovarian granulosa cell tumor cells. Interestingly, the finding of saraclinib (another Src inhibitor) is contrary to that of dasatinib as saracatinib does not improve efficacy of weekly paclitaxel in platinum-resistant ovarian cancer.

IL-6 is one of the cytokines and binds specifically to its receptor (IL-6R) to form IL-6/IL-6R complex, then recruits downstream molecular gp130 and ultimately develops as a trimer IL-6/IL-6R/GP130 complex. This trimer gives rise to activation of STAT3. The IL-6/gp130/STAT3 signaling is frequently activated in tumors and it may be developed as a target for cancer treatment and prevention. Guo et al have reported that siltuximab, a monoclonal anti-IL-6 antibody, significantly inhibits IL-6-induced STAT3 activation and decreases the expression of STAT3 targeted gene in ovarian cancer cells. Moreover, siltuximab restores sensitivity to paclitaxel in paclitaxel-resistant ovarian cancer cell line in vitro. However, combination siltuximab with paclitaxel has limited effect on xenograft mouse model in vivo. Similarly, there is no clinical benefit from siltuximab monotherapy in patients with advanced/refractory ovarian cancer. Tocilizumab is a humanized IL-6R antibody. Treating clear cell carcinoma of the ovary with tocilizumab impairs the activity of cell invasion and improves sensitivity to chemotherapy. To date, a phase I clinical trial of tocilizumab is finished, finding that it is feasible and safe in EOC patients combined 8 mg/kg tocilizumab with doxorubicin or carboplatin. SC144, a first-in-class orally active gp130 inhibitor, shows cytotoxicity including induction of apoptosis and cell death in ovarian cancer cells but no in normal kidney epithelial cells and endometrial epithelial cells. Furthermore, SC144 inhibits tumor growth of xenografts in mouse without substantial toxicity to normal tissues.

At last, using RNA interference (RNAi) technology is another approach to block STAT3 signaling and such strategy has also been adopted in ovarian cancer cells. Despite the efficacy of siRNA in cancer treatment, siRNA has not been widely used in clinical because of its instability and unsatisfactory delivery systems. Hence, researchers have worked on numerous methods for overcome these carriers. Recently, an oncolytic adenovirus (M4), which selectively silences STAT3 expression by producing antisense STAT3 complementary DNA, greatly suppresses survival of ovarian cancer cells but sparing normal cells. In addition, M4 enhances cisplatin antitumor property in vitro and in vivo, and does not exert synergistic toxicity to liver when combined with cisplatin. These findings provide a rationale reason for M4 further research to develop as an antitumor agent in patients with ovarian cancer.

Conclusions
Ovarian cancer is one of leading cause of death among women. Conventional chemotherapy is a part of standard treatment in ovarian cancer. However, chemotherapy is poorly tolerated for patients as a result of severe adverse side effects and most of patients are on the road to chemoresistance. Therefore, it is urgent need to design alternative and complementary therapeutic strategies for circumventing this dilemma. Abnormally activated STAT3 has frequently been found in ovarian cancer cells and clinical specimens. Persistent activation of STAT3 enhances cell proliferation, survival, invasion, cancer stem cell-like characteristic, angiogenesis and drug-resistance in ovarian cancer. Hence, STAT3 provides us an attractive target for ovarian cancer treatment and prevention. To date, there are several natural and synthetic inhibitors targeting STAT3 signaling directly or indirectly. Some inhibitors show significant toxicity or have synergistic effects when combined with conventional chemotherapy both in vitro and in vivo but no or little, if any, on normal cells and tissues. However, in spite of great efficacy on cell lines, quite few inhibitors exhibit minimal activity in xenografts or in patients, possibly because of low bioavailability, bad delivery systems and complex environment in vivo. Researchers have adopted numerous ways to address these concerns. In all,
given the vital role of STAT3 in progress of ovarian cancer and the published reports on STAT3 inhibitors, it is our belief that strategy targeting STAT3 signaling will achieve a great success in clinic of ovarian cancer.

Acknowledgments

This work was supported by National Natural Science Foundation of China (81760544).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Igle JW. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-7.
2. Darnell J. STATs and gene regulation. Science 1997;277:1630-5.
3. Yu H, Jove R. STATs and cancer–new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
4. Xiong A, Yang Z, Shen Y, Zhou J, Shen Q. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancurs (Basel) 2014;9:56-77.
5. Fan GW, Cheng CK, Guastafon WC, Charon E, Zupi P, Wong RA, Chen J, Lui J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, et al. EGFR phosphorylates tumor-derived EGFVR/IIIa driving STAT/3 and progression in glioblastoma. Cell Gnist 2013;24:438-49.
6. Sun F, Li Y, Song L, Alvarez AA, Zhang W, Lv D, Tang J, Liu F, Chang Z, Hatakeyama S, Hu B, Cheng SY, et al. TRIM59 Promotes Gliomagenesisis by Inhibiting TC45 Dephosphorylation of STAT3. Cancer Res 2018;78:1792-804.
7. Darnell JJ, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:415-21.
8. Siven KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G, Bishayee A. Targeting the STAT3 signaling pathway in cancer: role of anti-angiogenic and anti-metastatic therapies. Biochem Biophys Res Commun 2014;445:138-44.
9. Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, Vinkemeier U. Getting the message across, STAT! Design principles of a STAT3-directed coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem 2003;278:29252-60.
10. Vinkemeier U. Getting the message across, STAT! Design principles of a STAT3-directed coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem 2003;278:29252-60.
11. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007;251:199-210.
12. Seo JM, Park S, Kim JH. Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. J Biol Chem 2012;287:13840-9.
13. Ma J, Zhang T, Novotny-Thermav D, Tan AL, Cao X. A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem 2002;278:29252-60.
14. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:185-203.
15. Camintra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
16. Vaughan S, Coward JL, Bast RJ, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drakein R, Etemadmoghadam D, Flieder M, Ghabra H, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Clin Oncol 2011;11:719-25.
17. Miklosy S, Hilliard TS, Turkson J. Therapeutic modulators of STAT pathways and transcriptional activation of STAT in tumor cell transformation. J Cell Biochem 2000;79:67-77.
18. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stit oncogene product in human ovarian carcinoma cells. Cytomem Oncol 2000;57:96-73.
19. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hump C, Lee H, Seiden MV. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006;12:5085-93.
20. Wang L, Liang J, Qiu Y, Wu J, Zhang N, Liu B, Wu Q, Bi W, Hu G, Li H, et al. Targeting IAK2/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther 2014;13:3077-46.
21. Abubaker K, Lawor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N. Inhibition of the JAK2/STAT3 pathways in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer 2014;14:317.
Grunstein MS, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Hypoxia-inducible factor-1, a potential therapeutic target. *Cell* 1999;94:630-5.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lencz C, Power L, Howard J, Luber B, Husse CM, et al. IL-6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. *Clin Cancer Res* 2011;17:2538-48.

Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Sinibaldi D, Coppola D, Heller R, Ellis LM, et al. Leukemia inhibitory factor functions in parallel with CAFs to promote neoplastic transformation of partially transformed breast cancer cells. *Cell Res* 2015;34:2297-308.

Banerjee P, Erehman J, Gohlke BO, Wilhelm T, Preissner R, Dunkel M. Super Cinnamon extract reduces VEGF expression via suppressing HIF-1α gene expression and inhibits tumor growth in mice. *Carcinogenesis* 2011;32:1540-9.

Bapat SA, Mali AM, Koppikar CB, Kurrey NK, Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. *Cancer Res* 2005;65:3205-9.

Ahmed N, Abu bakr K, Findlay J, Quinn M. Cancerous ovarian stem cells: obstacles targets for therapy but relevant to chemoresistance. *J Cell Biochem* 2011;113:241-14.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Ning Y, Cui Y, Li X, Cao X, Chen A, Xu C, Cao J, Luo X. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8-STAT3 signaling. *Biomed Pharmacother* 2018;103:262-71.

Ji T, Gong D, Han Z, Wei X, Yan Y, Fei D, Dong W, Wang J, Xia X, Li F, Hu W, Liu L, et al. Abnormal expression of constitutive STAT3 activity circumscribes cisplatin-resistant ovarian cancer. *Cell Cancer Res* 2013;19:431-19.

Peri N, Perin GB, Bossi E, Comi V, Paciolla E, Lattanzio V, Colacição C, Cazzador C, Riccardi G, et al. Leukemia inhibitory factor functions in parallel with CAFs to promote neoplastic transformation of partially transformed breast cancer cells. *Cell Res* 2015;249:109-15.

Chen G. Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling. *FEBS J* 2015;282:1111-25.

Ning Y, Cui Y, Li X, Cao X, Chen A, Xu C, Cao J, Luo X. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8-STAT3 signaling. *Biomed Pharmacother* 2018;103:262-71.

Ji T, Gong D, Han Z, Wei X, Yan Y, Fei D, Dong W, Wang J, Xia X, Li F, Hu W, Liu L, et al. Abnormal expression of constitutive STAT3 activity circumscribes cisplatin-resistant ovarian cancer. *Cell Cancer Res* 2013;19:431-19.

Peri N, Perin GB, Bossi E, Comi V, Paciolla E, Lattanzio V, Colacição C, Cazzador C, Riccardi G, et al. Leukemia inhibitory factor functions in parallel with CAFs to promote neoplastic transformation of partially transformed breast cancer cells. *Cell Res* 2015;249:109-15.

Chen G. Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling. *FEBS J* 2015;282:1111-25.

Ning Y, Cui Y, Li X, Cao X, Chen A, Xu C, Cao J, Luo X. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8-STAT3 signaling. *Biomed Pharmacother* 2018;103:262-71.

Ji T, Gong D, Han Z, Wei X, Yan Y, Fei D, Dong W, Wang J, Xia X, Li F, Hu W, Liu L, et al. Abnormal expression of constitutive STAT3 activity circumscribes cisplatin-resistant ovarian cancer. *Cell Cancer Res* 2013;19:431-19.

Peri N, Perin GB, Bossi E, Comi V, Paciolla E, Lattanzio V, Colacição C, Cazzador C, Riccardi G, et al. Leukemia inhibitory factor functions in parallel with CAFs to promote neoplastic transformation of partially transformed breast cancer cells. *Cell Res* 2015;249:109-15.

Chen G. Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling. *FEBS J* 2015;282:1111-25.

Ning Y, Cui Y, Li X, Cao X, Chen A, Xu C, Cao J, Luo X. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8-STAT3 signaling. *Biomed Pharmacother* 2018;103:262-71.

Ji T, Gong D, Han Z, Wei X, Yan Y, Fei D, Dong W, Wang J, Xia X, Li F, Hu W, Liu L, et al. Abnormal expression of constitutive STAT3 activity circumscribes cisplatin-resistant ovarian cancer. *Cell Cancer Res* 2013;19:431-19.

Peri N, Perin GB, Bossi E, Comi V, Paciolla E, Lattanzio V, Colacição C, Cazzador C, Riccardi G, et al. Leukemia inhibitory factor functions in parallel with CAFs to promote neoplastic transformation of partially transformed breast cancer cells. *Cell Res* 2015;249:109-15.

Chen G. Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling. *FEBS J* 2015;282:1111-25.

Ning Y, Cui Y, Li X, Cao X, Chen A, Xu C, Cao J, Luo X. Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8-STAT3 signaling. *Biomed Pharmacother* 2018;103:262-71.
metastases—safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 2011;4:1419-25.

100. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Viskaduraki MA, Schuins AM, Piccirilli G, Brown K, Steward WP, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010;70:9003-11.

101. Piao Q, Brown VA, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010;70:7932-9.

102. Banerjee MP, Tripathi LM, Srivastava VM, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003;25:213-24.

103. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmernann BM. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine 2005;12:445-52.

104. Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnanabbi A, Zayed ME, Alhbari SA, Tan BK, Kumar AP, Sethi G. The multifaceted role of curcumin in cancer prevention and therapy. Phytomedicine 2015;22:278-86.

105. Dachsh CU. Curcumin targets inflammation and cancer. Endcrater Metam Infect Disord Drugs Targets 2015;15:88-96.

106. Kunnunakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cellular signaling proteins. Mol Cancer Res 2004;2:199-225.

107. Seo JH, Jeong KJ, Oh WJ, Sul HJ, Soon JS, Kim YK, Cho DY, Kang JK, Park CG, Lee HY. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett 2010;288:56-64.

108. Seo JH, Kim B, Cha T, Gwak HN, Tkaichi K, Song YN. Curcumin induces apoptosis by inhibiting sacro/endoplasmic reticulum Ca^2+ ATPase activity in ovarian cancer cells. Cancer Lett 2016;373:30-7.

109. Yu Z, Wan Y, Liu Y, Jiang J, Li L, Zhang W. Curcumin induced apoptosis via PERK/ATK-signaling pathways in SKOV3 cells. Pharn Biol 2016;44:2026-32.

110. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Soy AOK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2017;23:3432-40.

111. Sharma RA, Eudan SE, Patlon SL, Cooke DN, Shafayat AK, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Firmed Mohamed M, Chen ACJ. Phase I clinical trial of onartuzumab: systemic activity and compliance. Clin Cancer Res 2004;10:6847-54.

112. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcinouldin formulation. BMC Complement Altern Med 2006;6:30.

113. Cheng AL, Hsu CH, Lin JK, Hsueh MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, et al. Phase I clinical trial of curcumin, a nonsteroidal anti-inflammatory drug and natural antioxidant in volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010;70:2099-17.

114. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule STAT3 inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-42.

115. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule STAT3 inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-42.

116. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, Zhang JT, Liu ZM, Cui Y. Small-molecule compounds targeting the STAT3 DNA-binding domain inhibit survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. J Cell Biol 2018;212:1218-36.

117. ElNaggar AC, Bravo V, Levine P, Houghton P, Hidae K, et al. HO-3867, a safety STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res 2014;74:2316-27.

118. Selvendiran K, Tong L, Bratsas M, Kuppusamy LS, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kaliai T, Hidek K, Kuppusamy P. Anticancer efficacy of a difluororidarylenipiperidine (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 2010;9:1169-79.

119. Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy LS, Bratsas M, Rivera BK, Kaliai T, Hidek K, Kuppusamy P. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 2010;8:1188-97.

120. ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagame N, Kuppusamy P, Cohn DE, Selvendiran K. Anticancer potential of diarylidenyl piperidine derivatives, HO-4200 and HO-4136, in cisplatin resistant primary ovarian carcinoma. Cancer Res 2013;73:1705-17.

121. Wang H, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, He Y, Hangoc G, Pollok K, Sandusky G, Fu XY, Brommeyer HE, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, angiogenesis and STAT3 target gene expression in vivo. Oncogene 2016;35:2783-92.

122. Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, Zhang JT, Liu ZM, Cui Y. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. J Cell Biol 2018;212:187-97.

123. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grundis GR. Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 2010;107:4388-43.

124. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy development. Cancer Discov 2012;2:694-705.

125. Zhang X, Liu P, Zhang B, Mao H, Shen L, Ma Y. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. Int J Mol Med 2013;32:623-8.

126. Schaft J, Sperling R, Holis A, Matt KG, Berg T. Small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-42.

127. Becker S, Groner B, Muller CW. Three-dimensional structure of the Statbeta homodimeric protein. Nature 1998;394:145-51.

128. Yang P, Chang M, Malwana T, Siddiqi F, Swadlu J, Axonovich SA, Holmzeyer TA, Roninson IB. Identification of potential anticancer drugs through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 2003;4:411-53.

129. Timofeeva OA, Tatsurova NN, Zhang X, Chovscharovskikh S, Cheema AR, Wang H, Brown ML, Dritschilo A. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A 2013;110:1267-72.

130. Schust J, Sperl B, Hollis A, Matt KG, Berg T. Small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006;13:1235-42.
Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecol Oncol 2017;144:621-30.

McNeish IA, Ledermann JA, Webb B, James L, Kaye SB, Hall M, Hall G, Clamp A, Earl H, Banerjee S, Kristeleit R, Raju F, et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. J Clin Oncol 2012;30:1988-95.

Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamashita K, Taga T, Kishimoto T. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808-10.

Klein JD, Schoeller SK, Crabtree GR. Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol 1998;16:569-92.

Garbers C, Aparicio-Siegmann S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Pharmacol 2015;21:74-82.

Chen X, Tian J, Su GH, Lin J. Blocking IL-6/GP130 signaling inhibits cell viability/proliferation, glycosylation, and colony forming activity in human pancreatic cancer cells. Curr Cancer Drug Targets 2018.

Yan Y, Nemeth J, O’Brien C, Sura M, Liu X, Zhang Z, Chey M, Mankin H, Hornick F, Duan Z. Effects of silixumab in the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 2010;16:579-69.

Angevin E, Tabernero J, Ellez E, Cohen SJ, Bahlleda R, van Laethem JL, Ottensteiner C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, et al. A phase I/II, multiple-dose, dose-escalation study of silixumab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2014;20:2192-204.

Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura Y, Yamada K, Shimamoto A. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Cancer Ther 2016;15:832-41.

Dijkgraaf EM, Santegoets SJ, Rayens KR, Goedemans R, Wouters MC, van der Meulen J, van der Hoeven J, Weijers MJ, van der Burg SH, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 2015;26:2141-9.

Xu S, Grande F, Garofalo A, Neumann M. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther 2013;12:9374-9.

Zhao Y, Zheng C, Zhang L, Chen Y, Ye Y, Zhao M. Knockdown of STAT3 expression in SKOV3 cells by biodegradable siRNA-PLGA/C50 conjugate micelles. Colloids Surf B Biointerfaces 2015;127:155-63.

Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-38.

Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, Hu W, Yan Y, Feng J, Liao S, Wu P, Wang D, et al. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. Hum Gene Ther 2012;23:32-45.